Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
Pharmacological Research, 2022 Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that accounts for about 15% of all cases of leukemia. This disorder results from the formation of the Philadelphia chromosome that involves a reciprocal translocation that produces a lengthened chromosome 9 and shortened chromosome 22 - the Philadelphia chromosome.
R. Roskoski
semanticscholar +3 more sources
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib [PDF]
Blood Cancer Journal, 2015 Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
A. Zhou +4 more
semanticscholar +2 more sources
New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. [PDF]
Blood, 1990 A new and rare type of Bcr/Abl junction between exon C3 of the 3′ portion of the Bcr gene and Abl exon 2 has been identified in the leukemic cells of two Ph1-positive chronic myelogenous leukemia patients in chronic phase. This is the fourth type of Bcr/Abl junction so far identified in Ph1-positive hematologic malignancies and is a consequence of an ...
G. Saglio +8 more
semanticscholar +5 more sources
Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells [PDF]
Cell Research, 2008 This study examined the signaling events induced by shikonin that lead to the induction of apoptosis in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells (e.g., K562, LAMA84). Treatment of K562 cells with shikonin (e.g., 0.5 muM) resulted in profound induction of apoptosis accompanied by rapid generation of reactive oxygen species (ROS ...
X. Mao, Chunrong Yu, Wen Li, Wen Xin Li
semanticscholar +3 more sources
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice [PDF]
Leukemia, 2012 Although BCR-ABL+ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease. Besides cytotoxic T cells, natural killer (NK) cells may have a role in immune control of CML.
C. Chen +11 more
semanticscholar +3 more sources
BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia. [PDF]
Blood, 1991 Abstract Leukemia cells from adults with Philadelphia (Ph1)-chromosome positive chronic myelogenous leukemia (CML) have a characteristic molecular rearrangement between the BCR and ABL genes whereby major breakpoint cluster region (Mbcr) exons 2 or 3 are joined to ABL exon II.
I. Aurer, A. Butturini, R. Gale
semanticscholar +4 more sources
Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
The Oncologist, 2008 Abstract Learning Objectives After completing this course, the reader will be able to: Distinguish the exogenous causes of acute and chronic myelogenous leukemia.Discuss the evidence establishing the exogenous causes of secondary leukemia.Describe the relationship of radiation and chemical exposure to
M. Lichtman
semanticscholar +3 more sources
Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia [PDF]
Leukemia, 2001 To investigate the mechanisms behind the leukemic expansion of BCR/ABL-positive chronic myelogenous leukemia (CML), we examined the cell cycle status of hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) of 37 patients with newly diagnosed BCR/ABL-positive CML.
A. Krämer +4 more
semanticscholar +3 more sources
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients [PDF]
Blood, 1993 Abstract We report here the results of polymerase chain reaction (PCR) for bcr- abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 ...
K. Miyamura +9 more
semanticscholar +5 more sources
T-Lymphoblastic Leukemia With t(9;22): Blast Phase of Chronic Myelogenous Leukemia or BCR-ABL- Positive T-Acute Lymphoblastic Leukemia? [PDF]
American Journal of Clinical Pathology, 2012 T-acute lymphoblastic leukemia/lymphoma (T-ALL) as chronic myelogenous leukemia blast phase (CML-BP) is rare. BCR-ABL–positive T-ALL is extremely rare. In patients without previous/concurrent history of CML, it is difficult to differentiate these 2 entities. Herein we report 3 cases of T-ALL with t(9;22) and review the literature.
Jie Xu, Shaoying Li
semanticscholar +2 more sources